Multiple myeloma drug market forecast to reach $7.2 billion in 2021

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in 2011 to $7.2 billion in 2021 (a 5.2% annual growth) in the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from health care advisory firm Decision Resources.

The Pharmacor advisory service entitled Multiple Myeloma finds that market growth will be driven by increasing penetration of US biotech firm Celgene’s (Nasdaq: CELG) Revlimid (lenalidomide) into the first-line setting and its use in combination with emerging therapies across all lines of treatment.

Revlimid and Takeda (TYO: 4502) and Johnson & Jonson’s (NYSE: JNJ)/Janssen-Cilag/Janssen’s Velcade (bortezomib) will experience increasing uptake in the relapsed/refractory setting because they will be used in combination with emerging therapies. Revlimid will be used in combination with Onyx Pharmaceuticals/Ono Pharmaceutical’s Kyprolis, Takeda/Millennium’s MLN9708 and Bristol-Myers Squibb/Abbott’s elotuzumab. Velcade will experience increased uptake in combination with AEterna Zentaris/Yakult Honsha’s perifosine and Novartis’ panobinostat.